U.S. markets closed

Ocular Therapeutix, Inc. (OCUL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.50+0.61 (+3.84%)
At close: 4:00PM EDT

16.50 0.00 (0.00%)
After hours: 4:12PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close15.89
Open16.15
Bid16.46 x 800
Ask17.25 x 800
Day's Range16.05 - 17.00
52 Week Range4.76 - 24.30
Volume455,293
Avg. Volume952,391
Market Cap1.255B
Beta (5Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-2.56
Earnings DateMay 06, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Motley Fool

    Can Ocular Therapeutix Reach Its Full Potential?

    Ocular Therapeutix (NASDAQ: OCUL) recently reported fourth-quarter earnings with a loss of $85.6 million. While sales of Dextenza, Ocular's only approved therapeutic, were up an impressive 28% quarter over quarter, the drug's sales of $7 million are still a far cry from its potential peak sales of $600 million or more. In this video from Motley Fool Live, recorded on March 15, Fool.com contributors Brian Orelli and Keith Speights discuss the future of Ocular Therapeutix and how investors should be valuing the biotech.

  • Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates
    Zacks

    Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.78% and -4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update
    Business Wire

    Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided updates on its leading ophthalmology pipeline.